The PISA-II (short-term anti-TNF therapy with surgical closure vs anti-TNF therapy in the treatment of perianal fistulas in Crohn's disease) trial followed 88 patients with perianal CD comparing long-term outcomes of anti-TNF with surgical closure (n = 35) or anti-TNF monotherapy (n = 53). Here, TNF is linked to Crohn disease.